


ALCMI

‘al-kə-mē



ADDARIO LUNG CANCER
MEDICAL INSTITUTE

SUNDAY
3 JULY 2011
13:30-15:00

SATELLITE SYMPOSIUM

www.alcmi.net

ADDARIO LUNG CANCER MEDICAL INSTITUTE (ALCMI)

SATELLITE SYMPOSIUM

IASLC 14TH ANNUAL WORLD CONFERENCE ON LUNG CANCER
Amsterdam, The Netherlands

Although the literature has shown that the molecular testing of tumor/blood can improve patient outcomes, only a minority of physicians routinely order these tests. This symposium will provide community-based clinicians and academic/industry investigators with case studies on how a patient-founded research organization, in partnership with a key group of motivated investigators, is helping to catalyze and accelerate translational research while simultaneously supporting the integration of currently available molecular analyses into clinical practice for informed decision-making and improved patient outcomes.

ALCMI is non-profit translational research consortium focused on significantly improving overall survival by catalyzing and accelerating discovery and delivery of new and more effective treatment options.

THE WAY FORWARD FOR MOLECULAR DIAGNOSIS AND TREATMENT IN LUNG CANCER

LOCATION: ELICIUM I, RAI AMSTERDAM

Chairs	<i>Rafael Rosell (Spain) • Giorgio V. Scagliotti (Italy)</i>
13:30	Introduction: Challenges and Opportunities for the Next Five Years
13:35	The Time is Now: Biospecimen Collection, Networking and Fast-track Molecular Analyses <i>Harvey I. Pass, USA</i>
13:50	Integration of Molecular Testing into Clinical Workflow and Informed Decision-Making <i>David P. Carbone, USA</i>
14:05	Accelerating Discoveries to Patients: Driving Academic-Industry Collaborations <i>David M. Jablons, USA</i>
14:20	ALCMI: A Collaborative Model for Biospecimen Collections and Translational Research <i>Steven W. Young, USA</i>
14:25	Impact of Advocacy Organizations: A Case Study on Patient-Founded/Funded/Focused Transformational Research Efforts <i>Bonnie J. Addario, USA</i>
14:40-	Panel Discussion: Catalyzing Effective International Collaborations to Make Lung Cancer a Survivable Disease <i>Bonnie J. Addario, USA • David P. Carbone, USA David Gandara, USA • David M. Jablons, USA Pasi A. Jänne, USA • Silvia Novello, Italy Harvey I. Pass, USA • Rafael Rosell, Spain Steven W. Young, USA</i>

CHAIRS



Rafael Rosell, MD, PhD, is Chief, Medical Oncology Service at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol in Badalona (Barcelona), and Chairman of Pangaea Biotech, S.L.



Giorgio V. Scagliotti, MD, PhD, is Professor of Respiratory Medicine at the University of Torino. Dr. Scagliotti earned his medical degree and completed the postgraduate training in respiratory medicine, internal medicine, and medical oncology at the University of Torino. He is chief of the Thoracic Oncology Division at the S. Luigi Hospital, Orbassano (Torino) and Head of the Department of Clinical and Biological Sciences at University of Torino.

FACULTY



Bonnie J. Addario, a 7-year Lung Cancer Survivor, is Founder and Chair of the Bonnie J. Addario Lung Cancer Foundation, a San-Francisco-based non-profit organization that is one of the largest philanthropies devoted exclusively to increasing the survival rate of Lung Cancer through research, early detection, education, prevention, and treatment. Bonnie is also the Founder and member of the Board of Directors of ALCMI.



David Carbone, MD, PhD, is the Harold L. Moses Professor of Cancer Research, Professor of Medicine and Cancer Biology at the Vanderbilt University Medical Center and Director of Thoracic Head & Neck Cancer Program at the Vanderbilt-Ingram Cancer Center. He is also Director and Principal Investigator of the Vanderbilt Specialized Program of Research Excellence (SPORE) in Lung Cancer.



David Gandara, MD, is Professor of Medicine at the University of California, Davis School of Medicine, and serves as Associate Director of Clinical Research and Director of Thoracic Oncology at the University of California, Davis Cancer Center. Dr. Gandara is President of the International Association for the Study of Lung Cancer (IASLC) and serves on the Board of Directors.




David M. Jablons, MD, is Professor and Chief of Thoracic Surgery at the University of California, San Francisco, and Ada Distinguished Professor of Thoracic Oncology at the UCSF Helen Diller Comprehensive Cancer Center, where he also serves as Program Leader of Thoracic Oncology. Dr. Jablons is also co-founder of the Bonnie J. Addario Lung Cancer Foundation.




Pasi A. Jänne, MD, PhD, is Associate Professor of Medicine at Harvard Medical School and Assistant Physician at the Dana Farber Cancer Institute in Boston. He was one of the investigators who initially discovered EGFR mutations in 2004 and has subsequently studied their effect on clinical outcome of patients and on mechanisms of resistance. He was elected to the American Society of Clinical Investigation in 2008.



Silvia Novello, MD, PhD, is Assistant Professor of Respiratory Medicine at the Department of Clinical and Biological Sciences of the University of Turin, involved in many clinical trials evaluating new approaches in diagnosis and lung cancer therapy. She is also the President of WALCE (Women Against Lung Cancer in Europe), a non-profit European Association founded in 2006 in Turin.



Harvey I. Pass, MD, is Professor of Cardiothoracic Surgery and Surgery, and the first Division Chief of Thoracic Surgery/Thoracic Oncology at NYU School of Medicine. His previous positions include Chief, Thoracic Oncology at the Karmanos Cancer Institute, and Head of the Thoracic Oncology Section of the National Cancer Institute (NCI) for the National Institutes of Health.



Steven W. Young is President and Chief Operating Officer of ALCMI. He previously served as the Executive Director of the Multiple Myeloma Research Consortium (MMRC), a non-profit corporation that developed and implemented novel biorepositories, data systems, and scientific cores linking investigators and clinicians from academia, the community, and the biopharmaceutical industry.

ALCMI members not pictured: Paul Hesketh, MD, PhD, Ite Laird-Offringa, PhD and Tony Addario, Board Chair and CEO.

ALCMI

HELPING TO TRANSFORM THE STANDARD OF CARE FOR LUNG CANCER

ALCMI is a patient-founded, patient-focused research consortium. Its goal is to make Lung Cancer a survivable disease.

ALCMI was created in 2008 as a partner of the Bonnie J. Addario Lung Cancer Foundation (BJALCF) after being identified as a crucial need by more than 70 of the world's leading Lung Cancer researchers, clinicians and patients at a BJALCF-sponsored Summit held in late 2007.

ALCMI is unique. It is a comprehensively *contracted* consortium with shared infrastructures (standardized contracts, data systems and biorepositories) and centrally coordinated scientific planning. ALCMI's researchers are pooling their knowledge, specimens and data in order to improve the understanding of the molecular bases of Lung Cancer and to accelerate the development and delivery of much more effective, targeted drugs and treatments tailored to individual patients.

ALCMI represents a paradigm shift in the approach to making Lung Cancer a manageable disease. It is about finding solutions NOW. Not tomorrow. Not for future patients. ALCMI is making a difference—right NOW.

COLLABORATING INSTITUTIONS

- Catalan Institute of Oncology—Barcelona, Spain
- Dana-Farber Cancer Institute—Boston, MA, USA
- Hoag Hospital—Newport Beach, CA, USA
- Lahey Clinic Hospital—Burlington, MA, USA
- New York University—New York, NY, USA
- U. of California at Davis—Sacramento, CA, USA
- U. of California San Francisco—San Francisco, CA, USA
- University of Southern California, Los Angeles, CA, USA
- University of Torino—Turin, Italy
- Vanderbilt University—Nashville, TN, USA

For more information on collaboration and funding opportunities, please contact:
Steven Young at syoung@alcmi.net
+1.203.226.5765 (USA)

www.alcmi.net